RET and medullary thyroid gland carcinoma: With more selective RET inhibitors like Selpercatinib, a considerable response was recorded in patients initially treated with Vandetanib and/or Cabozantinib, and it was recently approved by the FDA for treating advanced RET-mutated MTC.